Skip to content

Safety assessment of products on skin

Evaluation of primary irritation potential in adult human subjects (Single 24-hour application)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019182
Enrollment
24
Registered
2019-05-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1. Cream (batch no. MNC-01) 2. Cream (batch No MLC-02) 3. Shampoo (batch No. MCS-03) 4. Face Pack (batch No. MTFP-04) 5. Lotion (batch No. MMCR-05) 6. Face Wash (batch No. MCFW-06) 7.

Sponsors

Terrai Natural Products
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 18-65 years (both inclusive) at the time of consent. 2. Sex: Males and non-pregnant/non-lactating females (preferably equal numbers of males and females). 3. Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application. 4. Subjects who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results. 5. Subjects in good general health as determined by the Investigator on the basis of medical history. 6. Subjects willing to maintain the test patches in designated positions for 24 Hours. 7. Subjects willing and able to follow the study directions, to participate in the study, returning for all specified visits. 8. Subjects must be able to understand and provide written informed consent to participate in the study. 9. Subjects willing to refrain from vigorous physical exercise during the study period.

Exclusion criteria

Exclusion criteria: 1. Female subject is pregnant, planning for pregnancy, or lactating. 2. Subjects having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos, scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading. 3. Medication which may affect skin response and/or past medical history. 4. Subjects having history of diabetes 5. Subjects have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months. 6. Subjects suffering from any active clinically significant skin diseases which may contraindicate. 7. Subjects having history of any skin diseases including eczema, atopic dermatitis or active cancer. 8. Participation in any patch test for irritation or sensitization within the last four weeks. 9. Subjects having history of asthma or COPD (Chronic obstructive pulmonary disease). 10. Subjects with Self-reported Immunological disorders such as HIV positive, AIDS and systemic lupus erythematous. 11. Individual who has a medical condition or is taking or has taken a medication which, in the Investigatorâ??s judgment, makes the subject ineligible or places the subject at undue risk. 12. Subject with known allergy or sensitization to medical adhesives, bandages. 13. Participation in other patch study simultaneously. 14. Use of any: I. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. II. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. III. Systemic or topical corticosteroids at patch site within four (4) weeks of Test Article application (steroidal nose drops and/or eye drops are permitted) IV. Topical drugs used at application site

Design outcomes

Primary

MeasureTime frame
Safety assessment of productsTimepoint: Irritation scoring at 30 minutes, 24 hours and 168 hours post patch removal

Secondary

MeasureTime frame
Not applicableTimepoint: Not applicable

Countries

India

Contacts

Public ContactMs Maheshvari Tamboli

Cliantha Research

nayan.patel@karmiclifesciences.com9909013286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026